A Phase 1 interventional study of ALN-TTRSC04 and Placebo in Transthyretin-Mediated Amyloidosis, sponsored by Alnylam Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Amyloidosis by Alnylam Pharmaceuticals — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis · Alnylam Pharmaceuticals.
Among the 22 studies in Amyloidosis by Alnylam Pharmaceuticals, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 1, and was the 18th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →6 of the 22 studies in Amyloidosis by Alnylam Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Germany, Japan
Ages 18+
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Brazil, Bulgaria and 9 more countries
Alnylam Pharmaceuticals · Sites in United States, France, Germany and 4 more countries
Women only
By country, each count listing its studies:
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2023.
This study's enrollment of 96 is above the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 96 across the 15 interventional studies, 67 across the 5 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Amyloidosis by Alnylam Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered a single dose of ALN-TTRSC04.
Drug: ALN-TTRSC04
Participants will be administered a single dose of placebo.
Drug: Placebo
ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
Placebo will be administered by SC injection.
Frequency of Adverse Events
Time frame: Up to 20 months
Change from Baseline in Serum Transthyretin (TTR) Levels Over Time
Time frame: Up to 18 months
Maximum Observed Plasma Concentration (Cmax) of ALN-TTRSC04
Time frame: Day 1 up to Day 4
Time to Maximum Observed Plasma Concentration (Tmax) of ALN-TTRSC04
Time frame: Day 1 up to Day 4
Area Under the Concentration-time Curve (AUC) of ALN-TTRSC04
Time frame: Day 1 up to Day 4
Fraction of ALN-TTRSC04 Excreted in the Urine (fe)
Time frame: Up to Day 2
Plan to share: No
Ran from Jan 2023 to primary completion in Sep 2025, 32 months.
Of 18 phase 1 interventional studies under Amyloidosis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 58. This study's 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nucresiran